Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (62)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. Lung Cancer Screening in People With COPD: The Pamplona-IELCAP Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 95-100

  3. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

  4. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

  5. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  6. Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma

    Gut

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

2022

  1. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  2. Cancer vaccines: the next immunotherapy frontier

    Nature Cancer, Vol. 3, Núm. 8, pp. 911-926

  3. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  4. Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy

    Journal of Hepatology

  5. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

    Journal of Translational Medicine, Vol. 20, Núm. 1

2021

  1. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

  2. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

  5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

  6. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 931-942

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18